Zacks Research Reduces Earnings Estimates for AXIS Capital
Investment analysts at Zacks Research cut their Q1 2025 earnings per share estimates for shares of AXIS Capital in a research ...
KBW Sticks to Their Buy Rating for Axis Capital (AXS)
KBW analyst Meyer Shields maintained a Buy rating on Axis Capital (AXS – Research Report) today and set a price target of $118.00. The ...
The Edge Singapore4d
Chocolate Finance CEO says disabling of AXS payments was 'communicated poorly'
A rush among users to withdraw funds forced the firm to temporarily suspend instant withdrawals, but founder and CEO Walter ...
FintechNewsSG2d
High AXS Payments Forced Chocolate Finance to Adjust Miles Rewards, Instant Withdrawals
Chocolate Finance paused instant withdrawals due to a surge in AXS bill payments, driven by users maximising its miles reward ...
Axis Capital price target raised to $118 from $115 at Keefe Bruyette
Keefe Bruyette analyst Meyer Shields raised the firm’s price target on Axis Capital (AXS) to $118 from $115 and keeps an Outperform rating on ...
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome ...
Morningstar14d
Axs Dynamic Opportunity I
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Zacks Investment Research on MSN3h
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio ...